Publicado: 10/02/2021

WHO OKs AstraZeneca jabs for Covid variants, over-65s

WHO OKs AstraZeneca jabs for Covid variants, over-65s

Geneva (AFP) -

The AstraZeneca-Oxford Covid-19 vaccine can be used for people aged over 65, and also where coronavirus variants of concern are circulating, WHO experts said Wednesday, soothing fears about the jab.

The World Health Organization's Strategic Advisory Group of Experts on Immunization (SAGE) issued interim recommendations for when and how to use the two-shot vaccine, which has yet to receive WHO emergency use authorisation.

The announcement came after the vaccine suffered setbacks, raising questions about whether it should be used on older people, or in places where a variant of the virus first found in South Africa is circulating.

SAGE chief Alejandro Cravioto acknowledged the lack of data on the vaccine's efficacy for people aged over 65, which has prompted a number of countries to withhold recommending its use in older people, who are by far the most vulnerable to the virus.

But the experts concluded that given its performance with younger adults, 'it is likely that the vaccine will be found to be efficacious in older persons. The trial data indicate that the vaccine is safe for this age group.'

Cravioto told journalists: 'We feel that the response of this group cannot be any different from groups of a younger age.'

SAGE, he said, recommends it be used 'for 18 years and above, without an upper age limit'.

Cravioto said the experts were awaiting more specific data on the vaccine's efficacy in people over 65, but said it 'would not be appropriate' to wait with its recommendations.

'We have thousands of people dying,' he stressed.

'Anything we can do to use a product that might reduce that is totally justified, even if the information is not as complete as we would like.'

- Effectiveness against variants -

The experts also said they had discussed the effectiveness of the vaccine when faced with emerging coronavirus variants of concern, and in particular the one first spotted in South Africa.

The country has decided to put off using AstraZeneca jabs in a planned vaccination programme over concerns about their efficacy against the variant.

Alarm was raised when a South African study concluded the AstraZeneca vaccine provided only 'minimal' protection against mild to moderate Covid-19 caused by the variant.

But the WHO insisted more data was needed, pointing to the study's scope, methodology and small size.

And SAGE recommended Wednesday that the vaccine could be used 'even if variants are present in a country'.

The WHO's chief scientist Soumya Swaminathan said the benefits would 'far outweigh' any risks, as variants may not be the predominant strains circulating in that country.

The SAGE experts also said the vaccine proved more effective when the interval between the doses was extended to between eight and 12 weeks.

- Equitable distribution -

The Covax system was set up by WHO, the Gavi vaccine alliance and CEPI to procure Covid-19 jabs and ensure their equitable distribution worldwide.

The AstraZeneca vaccine accounts for almost all of the 337.2 million doses Covax is preparing to ship before July to some 145 countries, covering three percent of their combined population.

However, the AstraZeneca jab first needs emergency use authorisation from the WHO, which is set to make a decision next week. Only the Pfizer vaccine has so far received the WHO stamp of approval.

Gavi chief Seth Berkley called SAGE's announcement, which clears a path towards authorisation, 'excellent news'.

'We will continue with our plans to roll this vaccine out worldwide,' he said.

Andrew Pollard, from Oxford University's Vaccine Group, meanwhile said SAGE's recommendations were 'an important milestone in extending access to the Oxford-AZ vaccine to all corners of the world.'

But Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers and Associations, sounded a note of caution.

Despite the industry's desire for a swift and equitable rollout, 'we warn against setting unrealistic expectations given the inherent risk of vaccine development and the complexity of scaling up manufacturing from scratch,' he said.

Más en Zeta

Cirugía de cuatro horas

Cirugía de cuatro horas

20 February 2021
La exprimera dama (1990-1994) Ana Mae Díaz, viuda de Endara, fue sometida este sábado 20 de febrero en una mano que se fracturó en varias partes. Su hermana Jesse informó que se trató de un accidente en la finca familiar. No son todosDe los 51 albergues que operan en Panamá, uno es estatal y est...

Libertad económica y libre empresa

ZETA, (JEAN PIERRE LEIGNADIER*).- Desde su fundación hace 105 años, la Cámara de Comercio, Industrias y Agricultura de Panamá ha tenido como unos de sus pilares la defensa de la libertad económica y la libre empresa como factores indispensables para el progreso sostenido y sostenible del país. E...

Dr Gaitán: Cuidemos la educación del coronavirus.

ZETA PANAMÁ, (EDGARDO GAITÁN*).-UNICEF, se decanta por recomendar la apertura de las escuelas. Dice que los niños no son los supercotagiadores que se decía al inicio de la pandemia y que los adultos son los que contagian a los niños. Tremendas verdades de perogrullo, claro que si no hay escuela...

9 de enero 1964: La Gesta que cambió la historia

ZETA PANAMÁ, (BENJAMÍN COLAMARCO PATIÑO).- El país debe sustentarse en valores, en principios, en objetivos superiores que direccionen la interactuación social y fortalezcan la cohesión estatal-nacional de la República. Quienes nos identificamos con las luchas históricas de nuestro pueblo por pr...

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.